Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US
September 21 2017 - 2:00AM
YASTEST Press Release
21 September 2017
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's
Mode of Action at the SITC Meeting in the US
Immunicum AB
(publ; First North Premier: IMMU.ST) a biopharmaceutical company
advancing a novel immune-priming cancer treatment against a variety of solid
tumors, today announced that the Society for Immunotherapy of
Cancer (SITC) has accepted an abstract on ilixadencel's mode of
action for a poster presentation at the SITC
32nd Annual Meeting, held November
8-12, 2017 at the Gaylord National Hotel & Convention Center in
National Harbor, Maryland.
The poster titled "In vitro mode
of action of ilixadencel - a cell-based allogeneic immune primer
for intratumoral administration" will be presented by Immunicum's
Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will
announce the complete data through a press release following the
presentation. The date and time of the presentation will be
available through the event section on Immunicum's website once
public.
For more information, please contact:
Carlos de Sousa, CEO,
Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Investor relations, sweden
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: helena.stangberg@halvarsson.se
Investor and Media Relations EU/US
MacDougall Biomedical
Communications
Gretchen Schweitzer eller Stephanie May
Telephone: +49 89 2424 3494 or + 49 175 571 1562
E-mail: gschweitzer@macbiocom.com or smay@macbiocom.com
The Company's Certified Adviser is
Redeye AB
Telephone: +46 (0) 8 545 013 31
www.redeye.se
| about IMMUNICUM AB (PUBL) Immunicum is establishing a
unique immuno-oncology approach through the development of
allogeneic, off-the-shelf cell-based therapies. Our goal is to
improve survival outcomes and quality of life by priming the
patient's own immune system to fight cancer. The company's lead
product ilixadencel, consisting of pro-inflammatory allogeneic
dendritic cells, has the potential to become a backbone component
of modern cancer combination treatments in a variety of solid tumor
indications. Founded and based in Sweden, Immunicum is publicly
traded on the Nasdaq First North Premier. www.immunicum.com |
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2023 to Apr 2024
